Aptol Pharma ApS: Financial statements 2020
CVR: 39308967
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
Aptol Pharma ApS (CVR 39308967) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -137,000 and a net result of DKK -2,464 compared with DKK -2,348 the year before. Equity in the 2020 report amounted to DKK 50,000. The solvency ratio was 100%.
- Revenue
- DKK 0
- Gross Profit
- DKK -137,000
- Profit/Loss
- DKK -2,464
- Equity
- DKK 50,000
- Total Assets
- DKK 50,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | 0 | -137 t. | -2 t. | 50 t. | - |
| 2019 | 0 | -102 t. | -2 t. | 50 t. | - |
| 2018 | 0 | 89 t. | 129 t. | 50 t. | - |
How creditworthy is Aptol Pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
Aptol Pharma ApS has published its annual report for 2019. Revenue came to DKK 0, and the net result was DKK -2,348.
About Aptol Pharma ApS
Aptol Pharma ApS was a Danish company of the type Anpartsselskab based in København SV, founded in 2018. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named IBIO TECH ApS and Integrated biomedical technologies ApS. The company's owners include ADT HOLDING ApS, Tue Wenzel Kragstrup and Peter Andreas Nicolai Reumert Wagtmann. In 2024, the company reported a gross profit of DKK 2,442 and a net result of DKK -131,289 compared with DKK 307,979 the year before. Equity in the 2024 report amounted to DKK -140,336.